XML 39 R29.htm IDEA: XBRL DOCUMENT v3.25.2

Revenue from Contracts with Customers (Tables)

6 Months Ended

Jun. 30, 2025

Schedule of Provisions for Sales and Allowances

A rollforward of the Company’s provisions for sales discounts and allowances is as follows:

		Six Months Ended June 30, 2025
(In thousands)		Contractual Adjustments(1)				Discounts(2)				Product Returns				Other				Total
Beginning balance — December 31, 2024		$	228,978			$	43,645			$	50,507			$	13,297			$	336,427
Current provisions relating to sales in current year			263,018				196,845				13,049				43,096				516,008
Adjustments relating to prior years			(25,329	)			152				(4,601	)			(332	)			(30,110	)
Payments relating to sales in current year			(125,484	)			(182,256	)			—				(33,652	)			(341,392	)
Payments relating to sales in prior years			(128,250	)			(22,941	)			(5,503	)			(12,231	)			(168,925	)
Ending balance — June 30, 2025		$	212,933			$	35,445			$	53,452			$	10,178			$	312,008

1.“Contractual Adjustments” include “Medicaid Rebates” and “Medicare Part D” accruals

2.“Discounts” include “Chargebacks” and “Product Discounts”

Schedule of Revenue Related Reserves Included in Consolidated Balance Sheets

Total revenue-related reserves as of June 30, 2025 and December 31, 2024 included in the accompanying consolidated balance sheets are summarized as follows:

		June 30,				December 31,
(In thousands)		2025				2024
Reduction of accounts receivable		$	16,658			$	22,031
Components of accrued sales discounts, allowances and reserves			253,173				272,452
Components of other long-term liabilities			42,177				41,944
Total revenue-related reserves		$	312,008			$	336,427

Schedule of Contract Assets and Contract Liabilities

Total contract assets at June 30, 2025 were as follows:

(In thousands)		Contract Assets
Contract assets at December 31, 2024		$	4,990
Additions			3,766
Transferred to receivables, net			(7,332	)
Contract assets at June 30, 2025		$	1,424

Total contract liabilities at June 30, 2025 were as follows:

(In thousands)		Contract Liabilities
Contract liabilities at December 31, 2024		$	1,249
Additions			1,313
Amounts recognized into revenue			(1,984	)
Contract liabilities at June 30, 2025		$	578

Product sales, net

Schedule of Disaggregation of Revenues

During the three and six months ended June 30, 2025 and 2024, the Company recorded product sales, net, as follows:

		Three Months Ended June 30,								Six Months Ended June 30,
(In thousands)		2025				2024				2025				2024
VIVITROL		$	121,660			$	111,873			$	222,656			$	209,532
ARISTADA and ARISTADA INITIO			101,295				86,049				174,770				164,919
LYBALVI			84,280				71,351				154,302				128,358
Total product sales, net		$	307,235			$	269,273			$	551,728			$	502,809

Manufacturing and royalty revenues

Schedule of Disaggregation of Revenues

During the three and six months ended June 30, 2025 and 2024, the Company recorded manufacturing and royalty revenues from its collaboration arrangements as follows:

		Three Months Ended June 30, 2025												Six Months Ended June 30, 2025
(In thousands)		Manufacturing Revenue				Royalty Revenue				Total				Manufacturing Revenue				Royalty Revenue				Total
Long-acting INVEGA products(1)		$	—			$	30,315			$	30,315			$	—			$	48,060			$	48,060
VUMERITY			7,383				32,016				39,399				13,358				53,874				67,232
RISPERDAL CONSTA			3,812				8				3,820				12,927				22				12,949
Other			5,372				4,516				9,888				7,609				9,589				17,198
		$	16,567			$	66,855			$	83,422			$	33,894			$	111,545			$	145,439

		Three Months Ended June 30, 2024												Six Months Ended June 30, 2024
(In thousands)		Manufacturing Revenue				Royalty Revenue				Total				Manufacturing Revenue				Royalty Revenue				Total
Long-acting INVEGA products(1)		$	—			$	78,739			$	78,739			$	—			$	141,412			$	141,412
VUMERITY			9,863				25,371				35,234				21,987				44,501				66,488
RISPERDAL CONSTA			3,428				130				3,558				6,023				253				6,276
Other			6,989				5,338				12,327				22,300				10,215				32,515
		$	20,280			$	109,578			$	129,858			$	50,310			$	196,381			$	246,691

(1)“long-acting INVEGA products”: INVEGA SUSTENNA/XEPLION (paliperidone palmitate), INVEGA TRINZA/TREVICTA (paliperidone palmitate) and INVEGA HAFYERA/BYANNLI (paliperidone palmitate).

X

- Definition

Revenue related reserves included in consolidated balance sheets.

+ References

No definition available.

+ Details

Name:	alks_RevenueRelatedReservesIncludedInConsolidatedBalanceSheetsTableTextBlock
Namespace Prefix:	alks_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of allowance for credit loss on right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479319/326-20-50-13

+ Details

Name:	us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

+ Details

Name:	us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=alks_ManufacturedProductAndRoyaltyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: